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Mark C. Walters,1 Karen Hardy,1 Sandie Edwards,1 Thomas Adamkiewicz,2
James Barkovich,3 Francoise Bernaudin,4 George R. Buchanan,5 Nancy Bunin,6
Roswitha Dickerhoff,7 Roger Giller,8 Paul R. Haut,9 John Horan,10 Lewis L. Hsu,11
Naynesh Kamani,12 John E. Levine,13 David Margolis,14 Kwaku Ohene-Frempong,6
Melinda Patience,1 Rupa Redding-Lallinger,15 Irene A. G. Roberts,16 Zora R. Rogers,5
Jean E. Sanders,17 J. Paul Scott,14 Keith M. Sullivan18 for the Multicenter Study of Bone
Marrow Transplantation for Sickle Cell DiseaseWe conducted a prospective, multicenter investigation of human-leukocyte antigen (HLA) identical sibling
bone marrow transplantation (BMT) in children with severe sickle cell disease (SCD) between 1991 and
2000. To determine if children were protected from complications of SCD after successful BMT, we
extended our initial study of BMT for SCD to conduct assessments of the central nervous system (CNS)
and of pulmonary function 2 or more years after transplantation. In addition, the impact on gonadal function
was studied. After BMT, patients with stroke who had stable engraftment of donor cells experienced no
subsequent stroke events after BMT, and brain magnetic resonance imaging (MRI) exams demonstrated
stable or improved appearance. However, 2 patients with graft rejection had a second stroke after BMT. After
transplantation, most patients also had unchanged or improved pulmonary function. Among the 11 patients
who had restrictive lung changes at baseline, 5 were improved and 6 had persistent restrictive disease after
BMT. Of the 2 patients who had obstructive changes at baseline, 1 improved and 1 had worsened obstructive
disease after BMT. There was, however, significant gonadal toxicity after BMT, particularly among female
recipients. In summary, individuals who had stable donor engraftment did not experience sickle-related
complications after BMT, and were protected from progressive CNS and pulmonary disease.
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ful transplantation and to expand the availability of
transplantation to those who lack sibling donors.
Previously, we showed that children who had stable
engraftment of donor cells no longer experienced
sickle-related clinical events after transplantation,
and also that stable donor mixed chimerism was
sufficient for this clinical benefit [4]. We have extended
these initial findings by conducting routine evaluations
of organ function after BMT that might detect
subclinical evidence of progressive organ damage.
In addition, these studies have generated longitudinal
information based on extended follow-up about the
toxicity of transplantation. Together, these assess-
ments offer reassurance about the durable benefits of
transplantation in children who have sickle cell disease
(SCD) and more clearly define the long-term toxic-
ities. The findings also provide additional information
to families and their physicians about the long-term
risks and benefits of this therapeutic option for chil-
dren with SCD.METHODS
Patients \16 years of age with symptomatic
SCD (SS, SC, or Sb-thalassemia) who had an
HLA-identical family member donor (Hb, AA, or
AS) were considered for BMT. All individuals
were required to meet eligibility criteria as
reported earlier [1]. The initial study design in-
cluded follow-up through 2 years after enrollment.
A supplemental long-term follow-up study was ini-
tiated after patient accrual was completed in 2000.
This extended study collected additional results of
the long-term impact of transplantation 2 years
and longer after initial enrollment, as described
later. Patients were enrolled from 27 centers in
the United States and Europe (see the Appendix
for collaborating centers). The study was approved
by the institutional review board of Children’s
Hospital and Research Center, Oakland, and by in-
stitutional review boards or their equivalents at
each of the collaborating sites. All patients and/or
their parents or guardians gave written informed
consent for their participation.
The National Heart, Lung, and Blood Institute
appointed a data safety and monitoring board
(DSMB) for the purpose of monitoring patient safety
and the ethical conduct and progress of this investiga-
tion. The board consisted of 5 hematologists, a clinical
statistician, and a patient advocate.Treatment Regimen
Patients were prepared for transplantation with
a combination of oral busulfan (Bu, 14 mg/kg),cyclophosphamide (Cy, 200 mg/kg) and horse
antithymocyte globulin (ATG, 90 mg/kg) or CAM-
PATH Immunoglobulin (10 mg for 5 days) in lieu of
ATG.
Three patients (patients 9-11) received Bu (500 mg/
m2), Cy (200 mg/kg), and rabbit ATG (20 mg/kg), and
another (patient 6) received Bu (16 mg/kg), Cy (200
mg/kg), and ATG (80 mg/kg), as previously reported
[1]. After November 1994, all North American patients
had Bu pharmacokinetics performed with targeted
steady-state concentrations adjusted to 400-600 ng/
mL. Patients received a combination of methotrexate
(MTX) and cyclosporine (CsA) for the prevention of
acute graft-versus-host disease (aGVHD). Prophylaxis
with CsA was given for 6 months following transplan-
tation. Definition and grading of aGVHD and chronic
GVHD (cGVHD) have been described [5,6]. Before
transplantation, patients not receiving chronic transfu-
sion therapy underwent a partial exchange transfusion
to achieve a fraction of Hb S #30%. All patients re-
ceived supportive care for infection prevention after
transplantation, according to local institutional prac-
tice. In response to an apparent increased incidence of
neurologic complications after transplantation [7,8],
preventive measures were employed since June, 1993:
anticonvulsant prophylaxis with phenytoin initiated
with Bu dosing and continued for 6 months following
transplantation (or until CsA was discontinued), strict
control of hypertension, prompt repletion of magne-
sium deficiency, and maintenance of hemoglobin con-
centrations between 9 and 11 g/dL and platelet counts
.50,000/mm3, as previously described.Late Effects Evaluation
All 55 long-term survivors had late effects evalua-
tions performed. Brain magnetic resonance imaging
(MRI) examinations were requested in all patients
before, 1, and 2 years after transplantation, and reports
by the local radiologist and the MR images were
collected centrally. The MRI examinations were
performed for follow-up purposes only, and were not
obtained in response to new neurologic examination
findings or clinical complications. The local radiology
reports were compiled to create a summary of the
posttransplantation central nervous system (CNS)
outcomes for this analysis. In the long-term follow-
up phase of the study, brain MRI exams were requested
through 4 years after transplantation. To test the
validity of the local MRI reports submitted by individ-
ual participating centers, a subset of 7 brain MRI pre-
and post-BMT exams was evaluated in a blinded
fashion by 1 neuroradiologist (J.B.). This blinded
assessment included evaluation of the size (in millime-
ters), location, and number of cortical and white
matter abnormalities, and whether these had changed
since the prior scans. The scans had axial T1-weighted
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images through the entire brain. The lesions were
bright on T2-weighted images and dark on
T1-weighted images compared to normal brain.
For each set of images, it was determined if the lesions
were new or old and, if old, whether they were larger
than on the prior study. The signal intensity and
degenerative character of any abnormalities were also
noted, and the scoring was compiled using a standard-
ized worksheet to generate an overall comparison of
the blinded pre- and posttransplant MRI exams. An
examination was scored as improved if the number of
lesions was fewer and/or if the diameter of the cortical
or white matter abnormalities was smaller compared to
the baseline examination.
Similarly, pulmonary function tests (PFTs; total
lung capacity [TLC], forced vital capacity [FVC], re-
sidual volume [RV], and the ratio of forced expiratory
volume to FVC [FEV/FVC]) were measured before
and at annual intervals after transplantation. Spirome-
try and/or lung volumes (either by Nitrogen washout
and/or by body plethysmography) were measured.
Diffusion capacity was measured in 14 patients by
the single-breath diffusion technique. PFT usage was
based upon common methods for comparison of refer-
ence values [9]. The raw data were converted to a single
set of predicted values according to the method by
Polgar [10]. The following parameters were analyzed:
FVC, FEV1, FEV1%, TLC, RV, and carbon monox-
ide diffusing capacity (DLCO).
PFT results were segregated into 3 distinct cate-
gories of lung function: restrictive, obstructive, and
normal. Two standards were considered in defining
these categories: the American Thoracic Society
(ATS) 2007 guideline suggests that restrictive disease
is defined by having a TLC\80%, or by having an
FVC\75% if no TLC result is available. Obstructive
disease is defined by having a FEV1/FVC ratio\80%.
Lacking any accepted parameters for significant
change after BMT, we made the assumption that
a change was significant if it exceeded the percent pre-
dicted measure by .10%, a magnitude of change that
is not likely to be caused by measurement variability,
according to current published guidelines [11–13].
Finally, endocrine function tests (thyroid function
tests and luteinizing hormone [LH], follicle stimulat-
ing hormone [FSH], and estradiol or testosterone
assays) in serum were measured before and at annual
intervals after transplantation.Statistical Analysis
Statistical analyses were performed to summarize
results. The method of Kaplan and Meier was used
to estimate survival and EFS (where an event was
defined as death, graft rejection, or return of SCD)
[14]. A cumulative incidence curve for graft rejectionwas also calculated [15]. EFS was defined as survival
in the absence of clinical vaso-occlusive complications
typical of SCD with evidence of sustained donor
engraftment. Student’s t-test was applied to each of
5 PFT variables to evaluate for any significant changes
after BMT. Descriptive statistics were computed for
each pulmonary function variable.RESULTS
Outcome after Transplantation
The outcome after HLA-identical sibling BMT
has been updated from previous reports [4]. Fifty-
seven children with SCD (Hb SS), 1 with sickle b1-
thalassemia and 1 with sickle/O-Arab disease from
27 transplant centers in the United States, South
America, and Europe were enrolled in this collabora-
tive study between September 1991 and April 2000,
3 of whom were included in a previous publication
[3]. Fifty-five patients survive, and 50 survive free of
the underlying disease. Four patients died of trans-
plantation-related complications that included intra-
cranial hemorrhage or complications related to
GVHD. The median times to engraftment with an ab-
solute neutrophil count (ANC) .500/mm3 and plate-
let count .20,000/mm3 were 19 and 25 days,
respectively. Five patients experienced graft rejection
with recurrent SCD. The Kaplan-Meier probabilities
of survival and EFS are 93% and 85%, respectively,
with a median follow-up of 6.5 years (range: 3.0-
12.4) (Figure 1). The cumulative incidence of recur-
rent SCD was 9%. Most patients had stable engraft-
ment with .95% donor cells after BMT. However,
8 patients (15%) had\95% donor cells, of whom 6
had #70 % donor cells (Table 1) in this update of an
earlier report [16]. None of these 6 patients experi-
enced sickle-related complications after BMT and 1
patient received a single red blood cell (RBC) transfu-
sion beyond 90 days after transplantation. Long-term
follow-up evaluations were performed in all survivors,
including 4 patients who had graft rejection accompa-
nied by return of SCD and patients with stable mixed
chimerism. Engrafted patients were defined as having
full donor chimerism or having stable persistence of
donor cells sufficient to eliminate clinical and labora-
tory signs of SCD.
Seven patients (12%) developed grades II-IV
aGVHD after transplantation. The clinical grading,
sites of involvement and treatment of GVHD are sum-
marized in Table 2. Eight patients (14%) developed
cGVHD that was limited in 4, and extensive in 4.
Three patients with extensive cGVHD died of this
complication, and the other patients with cGVHD re-
covered completely and are no longer receiving immu-
nosuppressive therapy.
Figure 1. Survival probabilities and the cumulative incidence of graft
rejection after BMT for sickle cell disease. Kaplan-Meier probabilities
for survival and EFS after BMT for SCD are shown. An event was defined
as death, graft rejection or return of SCD. A cumulative incidence curve
for graft rejection/disease recurrence is also depicted.
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Twenty-nine of 59 patients had stroke or other
significant CNS disease as an indication for transplan-
tation and 28 survive after BMT. Surviving patients
with stroke who also had stable engraftment of donor
cells (N5 25) experienced no subsequent stroke events
after BMT. However, patients who had graft rejection
after BMT were not protected from stroke. One
patient with graft rejection experienced a second
stroke when the Hb S fraction reached 60% after
BMT and another patient with graft rejection had
a subarachnoid hemorrhage after BMT. In total, 28
of 29 (97%) patients with stroke survive after
transplantation, and 26 of 29 (90%) survive stroke-
free after BMT.
Most patients who survived after BMT also had
stabilization of the underlying cerebral vascular
disease, as evaluated by brain imaging studies (Table
3). Forty-six of 55 surviving patients who were
enrolled in the multicenter study had a brain MRI
performed after transplantation. These studies were
compared to pretransplantation baseline exams in all
but 4 of the patients. Of the 28 patients with stroke
studied after transplantation, except in the 2 patients
with graft rejection noted earlier, there was stableTable 1. Characteristics of Patients Who Had Stable Mixed
Chimerism (#70% Donor Chimerism) after BMT for Sickle
Cell Disease
Patient No. % Donor %S Hgb HCT
Txn >
D+90
Sickle
Symptoms
#13 13% 6% 10.8 33 Yes No
#16 70% 2% 13.1 39 No No
#18 60% 0 16.1 48 No No
#38* 20-30% 36.3% 11.6 33.4 No No
#49 62% 0 11.3 33.6 No No
#52* 55% 39% 11.7 34 No No
HCT indicates hematocrit; Hgb, hemoglobin; S, hemoglobin S; Txn, RBC
transfusion.
*Hb AS (trait) donor.appearance or lesions that had evolved to a smaller
size by brain MRI, documented by studies that were
performed a median of 3.2 (range: 0.6-7.3) years after
BMT. Ten patients had evidence of silent cerebral
infarction before transplantation. Of these 10, 8
patients had post-BMT studies performed a median
of 1.7 (range: 0.5-4.9) years after BMT, which were
stable in 3 patients and 4 patients had lesions that
had evolved to a smaller size by brain MRI. In 1 patient
who was enrolled for recurrent episodes of acute chest
syndrome and who had silent cerebral infarction
before BMT, additional small watershed lesions were
noted 1 month after transplantation, but this individ-
ual had a stable brain appearance in subsequent exams
through 5 years after BMT. There were no clinical
strokes after BMT in this group.
Sixteen patients had no documented CNS disease
before BMT (Table 3). All 10 studied in this group
had normal MRI appearance a median of 3.1 (range:
0.5-5.2 years) after BMT. In the 7 cases for which
a blinded adjudication was performed, the blinded
assessments were concordant with the MRI reports
submitted for review. Together, these observations
show that most patients had stabilization of cerebral
vasculopathy after BMT.
Initially in this cohort, seizures were observed
commonly after BMT [7]. As a result, anticonvulsant
therapy was routinely administered throughout the
duration of CSP use to reduce the risk of seizures.
Overall, 19 individuals had a neurogic event after
transplantation, including 2 episodes of intracranial
hemorrhage that was fatal in 1, a second thrombotic
stroke after graft rejection, and 16 with seizures. These
events occurred a median of 90 days after BMT (range:
6-1488 days). As noted previously, the episodes were
associated with hypertension, thrombocytopenia, or
relative polycythemia (hemoglobin level .11 g/dL),
and seizures were commonly associated with absent
or inadequate anticonvulsant blood levels. Generally,
these occurred in the first 6 months after transplanta-
tion; however, seizures occurred .6 months after
BMT in 2 patients with graft rejection and a history
of stroke. After the routine institution of preventive
guidelines to prevent neurologic events, 14 of 40
patients (35%) had events, although these were not
associated with long-term sequelae, and there were
no additional episodes of intracranial hemorrhage.
Of interest, these events occurred at a similar
frequency in patients who had or did not have preexist-
ing neurovascular disease, as shown in Table 3.Pulmonary Function after Transplantation
At the baseline, 25 of the 55 surviving patients
had pulmonary function abnormalities, with restric-
tive pulmonary disease being the most frequent find-
ing. Pulmonary function testing was performed in
Table 2. GVHD after HLA-Identical Sibling BMT for Sickle Cell Disease
Patient No. aGVHD (Grade/Site) cGVHD (Grade/Site) Treatment Outcome
1 II/skin Limited/skin CsA/pred resolved
9 III/skin Extensive/lung, liver CsA/Pred Died of GVHD
27 None Limited/skin none resolved
30 III/skin, GI, liver Extensive/GI, liver CsA/Pred/ATG/thalidomide Died of GVHD
34 III/skin, GI, liver Limited/oral CsA/Pred resolved
35 III/skin, GI, liver Extensive/skin, liver, GI CsA/tacrolimus/MMF/ATG/OKT3/sirolimus resolved
41 III/skin Extensive/skin, lung, oral Tacrolimus/pred/MMF/azathioprine Died of GVHD
51 II/skin Limited/skin CsA/pred resolved
aGVHD indicates acute graft-versus-host disease; ATG, antithymocyte globulin; BMT, bone marrow transplantation; cGVHD, chronic graft-versus-host
disease; CsA, cyclosporine; GI, gastrointestinal; HLA, human leukocyte antigen; MMF, mycophenolate mofetil; Pred, prednisone.
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these, 26 had baseline studies for comparing pre and
post-BMT pulmonary function results (Table 4).
Twenty-three patients had baseline and post-BMT
evaluations that included spirometry measurements.
Thirteen patients had diffusion capacity measured
before and after BMT. Of the 10 patients who had
no testing performed after BMT, 5 had normal
pulmonary function before BMT, 4 had restrictive
disease, and 1 had no testing before or after BMT.
The longest interval between baseline and post-
BMT pulmonary function testing was utilized for
this analysis. The time interval to testing after
BMT ranged from 0.2 to 10.6 years, with a median
of 3.2 years.
Of the 23 patients who were evaluable for compar-
ison of spirometry and lung volumetrics before and
after BMT, the mean predicted FEV1 changed from
88% 6 10% to 86% 6 11% (P 5 .59) and the mean
predicted FVC changed from 78% 6 16% to 81% 6
12% (P5 .45) after transplantation. Before transplan-
tation, 11 had restrictive changes, 2 had obstructive
changes, and 10 patients had normal lung function at
baseline (Tables 4 and 5). Among the 11 patients
who had restrictive changes at baseline, 4 had normal
function after BMT and 7 had persistent restrictive
changes. Of these 7, 1 was improved but continuedTable 3. Neurological Outcomes among Surviving Patients (N 5 5
Pre-BMT Status with
Duration Follow-up
(median, Range)
Ischemic Stroke
after BMT
Cerebral Hem
(ICH) after
‘‘Clinical’’ stroke [n 5 29]
(7.0, 3.4-12.4 yrs)
N 5 1 N 5 1 (S
‘‘silent’’ stroke [n 5 10]*
(6.7, 3.4-10.6 years)
N 5 0 N 5 0
Normal (N 5 16)†
(6.6, 3.1-11.1 years)
N 5 0 N 5 0
BMT indicates bone marrow transplantation; CNS, central nervous system; ICH
arachnoid hemorrhage.
†Including 4 with no baseline exam.
*‘‘Silent stroke’’ refers to individuals with MRI evidence of cerebrovascular disto have a restrictive pattern, 1 had more restrictive
disease, and 5 were unchanged after BMT. Of the 2
patients who had obstructive changes at baseline,
1 had normal pulmonary function after BMT, and 1
had worsened obstructive disease after BMT. Of the
10 patients who had normal lung pattern at baseline,
8 remained normal after BMT and 2 developed a re-
strictive pattern after BMT.
Compared to pre-BMT measurements, the RV
(P 5 .02) and RV/TLC (P 5 .03) were significantly
decreased after BMT. The observed difference in RV
and in RV/TLC suggests that there was decreased
air trapping and therefore improved lung function
after BMT. The DLCO was improved in 3 of 13
patients after BMT, but this was not statistically
significant. Overall, patients who had normal baseline
pulmonary function were likely to remain normal (8 of
10) after BMT. Patients who had restrictive disease at
baseline were likely to have improved or persistent, but
not progressive restrictive disease (10 of 11). Taken
together, these data show that most patients had stable
pulmonary function after BMT.
Posttransplantation Gonadal Function
The observations of gonadal function in males and
females after transplantation for SCD are presented in
Tables 6 and 7. All the survivors (33 male and 225)
orrhage
BMT
Seizure after
BMT
MRI Appearance after BMT
(Median Duration, Range in
Years after BMT)
AH) N 5 7 27/28 studied had stable or
improved MRI; 1 not
studied (3.2 years,
0.6-7.3)
N 5 4 All 8 studied had stable [4]
or improved [4] MRI; 2
not studied
(1.7 years, 0.6-4.9)
N 5 5 All 10 studied had normal
MRI; 6 not studied
(3.1 years, 0.5-5.2)
, intracranial hemorrhage; MRI, magnetic resonance imaging; SAH, sub-
ease without clinical manifestations.
Table 4. Summary of Pulmonary Function Test (PFT) Results before and after BMT for SCD
Patient No. Baseline Pattern Post-BMT FVC Change† FEV1/FVC Change† Baseline DLCO % Post-BMT DLCO Years Post-BMT
1 R R +12% (58%/ 70%) +9% 78 72 5
2 N N +4% +1% 64 64 1
6 N N +2% 28% 110 98 10
14 N N +6% +4% 46 86 2
15 R N* +12% (74%/ 86%) 22% 58 78 3
18 R R +7% 27% — — 3
19 N N -41% (126%/ 85%) +4% — — 3
21 N N 22% +4% — — 5
23 R R +2% 239% (121%/ 82%) 59 78 5
25 N R* 213% (78%/ 65%) +10% (87%/ 97%) — — 1
27 R R +6% 214% (85%/ 69%) — — 3
31 R R 25% +9% — — 1
32 O O 26% 215% (66%/ 51%) 90 99 6
33 N N +23% (84%/ 107%) +8% 88 118 5
42 R N* +27% (66%/ 93%) 216% (100%/ 84%) — — 1
44 R R 26% +4% 116 79 1
45 N R* 28% 23% 93 72 2
48 N N +7% +8% — — 2
51 O N* 28% +13% (75%/ 88%) 127 95 3
52 R N* +27% (56%/ 83%) +12% (88%/ 100%) — — 2
53 R R 211% (71%/ 60%) 210% (92%/ 82%) 108 103 1
56 R N* +13% (77%/ 90%) +3% 100 103 2
58 N N +6% 22 — — 2
DLCO indicates carbon monoxide diffusing capacity; FEV1/FVC, ratio of forced expiratory volume to forced vital capacity; FVC, forced vital capacity;
N, normal; O, obstructive; R, restrictive; SCD, sickle cell disease.
*Changed pattern after BMT.
†When the difference between the pre- and post-BMTresult was >10%, the value of the pre- and post-BMTmeasurement expressed as a percentage of
normal is shown in parentheses.
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than 14 years of age. The current median ages are 21.6
(range: 16.1-28.5 years) and 21.7 (range: 14.1-27.8
years) among the males and females, respectively.
Among these, 13 males (39%) and 14 females (64%)
had posttransplantation endocrine studies reported.
The LH and FSH levels were normal in 9 males and
less than normal in 4 after transplantation. However,
only 3 of 13 had normal testosterone levels (Table 6),
consistent with hypogonadotrophic hypogonadism in
most of the pubertal males. In contrast, 8 of 14 females
had increased gonadotropin levels and/or below
normal estradiol levels, a finding consistent with
primary ovarian failure in the majority of postpubertal
females. Only 4 of 14 females had normal estradiol
levels (Table 6). However, 1 female had a successful
pregnancy 13 years after BMT and another female
with graft rejection gave birth to a healthy baby follow-
ing preimplantation genetic diagnosis 14 years after
BMT, although she had experienced 2 previous spon-
taneous abortions several years earlier.Table 5. Pulmonary Function after BMT According to pre-
BMT Performance Status
Post-BMT Pulm
Function
Normal
(N 5 10)
Obstructive
(N 5 2)
Restrictive
(N 5 11)
Unchanged pattern 8 0 5
Improved N/A 1 (normal) 5 (normal in 4)
More restrictive 2 — 1
More obstructive — 1 —
BMT indicates bone marrow transplantation.DISCUSSION
These updated results confirm that children who
were treated by HLA-identical BMT have durable en-
graftment of donor cells and do not experience painful
or other clinical events related to SCD. We have ex-
tended these observations with findings that strongly
suggest that most individuals are also protected from
subclinical progression of end-organ pulmonary and
CNS dysfunction that is associated with vaso-occlu-
sion or other sickle-related pathophysiology. To-
gether, these observations reinforce the notion that
conventional BMT offers a favorable risk-benefit bal-
ance in children who have severe SCD. Unfortunately,
it was not possible to conduct a comprehensive cross-
sectional evaluation of pulmonary, gonadal, and CNS
status at regular intervals in all the subjects after trans-
plantation because of constraints of the original study
design, which was to demonstrate the safety and feasi-
bility of conducting a multicenter investigation of
HLA-identical sibling BMT for SCD. In the future,
however, transplantation study design should include
a systematic evaluation of the quality of survival after
successful transplantation and routine assessments of
organ function, particularly of the kidney, lungs, brain,
and endocrine system.
Although children who had stroke as an indication
for BMT were protected from clinical strokes after
successful transplantation, the long-term natural
history of neurovascular disease after transplantation
remains somewhat uncertain. It was not possible to
Table 6. Gonadotropin and Testosterone Levels in Males after BMT for SCD
Patient No. Age at BMT Current Age Age at Last Testing LH FSH Testosterone
2 10.6 25.4 12.9 Nl Nl Below normal
6 12.2 26.2 13.2 Nl Nl Below normal
14 12.3 22.2 13 Nl Nl Below normal
15 13.3 23.3 18.4 Nl Nl Below normal (Nl at 16.7 years)
16 10.1 20.1 13.7 Nl Nl Below normal at 12.5 years
18 8.2 17.7 11.7 Nl Nl Below normal
28 8.5 20.0 10.5 Below normal Below normal Below normal
32 7.4 18.5 13.7 Below normal Below normal Below normal at 10.5 years
33 12.8 23.4 18 Nl Nl Nl at 19 years
36 15.9 25.8 18.4 Nl Nl Not tested
40 12.5 21.9 16.7 Below normal Below normal Nl on HRT
56 10.8 15.3 11.9 Below normal Below normal Not tested
59 11.8 15.8 12.8 Nl Nl Nl
BMT indicates bone marrow transplantation; FSH, follicle stimulating hormone; HRT, hormone replacement therapy; LH, Luteinizing Hormone; Nl, nor-
mal; No., number; SCD, sickle cell disease.
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after transplantation as part of the long-term follow-
up evaluations; thus, the impact of successful BMT
on functional CNS status remains undefined in this
cohort. Although most patients with stroke or silent
cerebral infarction before BMT had no further
changes after BMT, 1 patient in this study had
progressive changes by MRI in the initial month after
transplantation that did not change in subsequent
examinations through 5 years after BMT. There is
a possibility that the natural history of neurovascular
injury might include reactive gliosis or other changes
related to the initial event that are not altered by the
transplantation itself. This possibility is also
supported by another retrospective clinical survey in
which radiographic changes were noted in some
patients with SCD who underwent transplantation
for stroke [17]. Five of 9 patients had either new or
slightly increased size of cerebral lacunae or leukoen-
cephaly that stabilized 2-7.5 years after transplanta-Table 7. Gonadotropin and Estradiol Levels in Females after BMT
Patient No. Age at BMT Current Age Age at Last Testing
1 10.5 26.5 16
3* 10.2 25 17.3
8 14 27.8 25.4
10 8.3 23.3 12.3
11 8.2 22.3 14.2
12* 13.7 27.6 18.8
20 12.2 24.8 15.5
23 8.6 20.6 14.2
26 12.4 24 21.1
27 6.0 17.6 11
29 9.7 21.1 14.5
38 4.3 14.1 10.5
39 13.7 23.3 14.9
45 9.5 18.7 14.4
47 10.3 19.5 12.9
51 9.6 18.3 14.5
57 11.2 19.3 16.5
BMT indicates bone marrow transplantation; FSH, follicle stimulating hormone
mal; No., number; SCD, sickle cell disease.
*Successful pregnancy and live birth after BMT.tion. Thus, it is possible that these observations
reflect the evolution of cerebrovascular disease that
existed before BMT. Of interest, these brain MRI
changes were not associated by progressive neurocog-
nitive deficits.
This study shows that children with stroke are
protected from a second stroke after BMT, when there
is durable engraftment of donor cells. Thus, it is clear
that transfusions for stroke prophylaxis can be stopped
after BMT. This contrasts sharply with the current
practice of regular RBC transfusions for stroke pro-
phylaxis that remains the standard of care outside suc-
cessful BMT. In 1 series of 137 pediatric patients from
14 centers (mean age at first stroke was 6.3 years) for
whom there was a mean follow-up of 10.1 years, 31
(22%) patients had a second stroke (2.2 per 100 patient
years) while receiving regular RBC therapy [18]. There
is also a risk of intracranial hemorrhage in adults who
had a childhood stroke [19]. We observed significant
CNS events (stroke or intracranial hemorrhage) in 3for SCD
LH FSH Estradiol Amenorrhea
— Increased Receiving HRT —
Nl Nl Not tested Yes
Increased Increased Decreased Yes
Increased Nl Decreased Yes
Increased Increased Decreased Yes
Nl Nl Nl No
Increased Increased Decreased —
Nl Nl Decreased Yes
Increased Increased Decreased Yes
Nl Nl Nl —
Nl Nl Nl No
— — — Yes
Increased Increased — —
Increased Increased Receiving HRT —
Nl Nl Nl Yes
Nl Nl Decreased No
— — Receiving HRT Yes
; HRT, hormone replacement therapy; LH, Luteinizing Hormone; Nl, nor-
270 Biol Blood Marrow Transplant 16:263-272, 2010M. C. Walters et al.of the 59 patients enrolled in this trial, and 1 patient
died of intracranial hemorrhage after BMT. Thus, it
appears that the intention to treat by transplantation
provides a similar level of protection from stroke, as
do regular transfusions. However, BMT is associated
with a risk of mortality and other significant morbid-
ities such as GVHD in the short-term, although these
risks are balanced by the elimination of chronic RBC
transfusions and iron chelation therapy in the long
term. Whether transplantation might also be a suitable
alternative in preventing a first stroke is less certain,
although in the series reported here, individuals with
silent cerebral infarction were protected from progres-
sive changes by brain MRI, and in some, the pre-BMT
changes resolved. Thus, it might also be appropriate to
consider BMT in children who have a high risk for
stroke and progressive neurologic injury [20–23].
Pulmonary function after BMT was, for the most
part, little changed after transplantation. Primarily,
this was interpreted to indicate that there was no addi-
tive functional impairment caused by the conditioning
regimen. However, in other pediatric series, progres-
sive obstructive spirometric changes were observed
more frequently after transplantation with Bu than af-
ter total body irradiation (TBI) [24]. However, there is
a growing body of evidence to indicate that the pulmo-
nary toxicity of SCD is progressive, and may be ex-
pressed as either restrictive or obstructive pulmonary
disease [25,26]. In a series from the Cooperative Study
of Sickle Cell disease, only 10% of adults had normal
PFT results, with restrictive pulmonary disease
(74%) accounting for the most frequent abnormality
among 310 adult SCD individuals tested [27]. The
rate of progression of pulmonary function abnormali-
ties is not certain, but in 1 series of children and ado-
lescents tested over 42 6 23 months, 56% had
normal PFTs at the baseline, and only 29% remained
normal at the second testing, with obstructive patterns
being observed more frequently than restrictive [28].
In another series of 413 children with SCD who had
pulmonary function testing results analyzed by a linear
mixed effects model, showed significant serial decline
in the percent predicted values for FEV1, FVC, and
FEF25-75 across age [29]. Thus, these data strongly
suggest that the negative impact of sickle vasculopathy
on pulmonary function is progressive. This type of
pulmonary injury appears to be halted by the establish-
ment of donor erythropoiesis and cessation of acute
chest episodes that we observed in this transplant co-
hort. We conclude, therefore, that successful trans-
plantation protects recipients from this effect of the
underlying disease.
Another pulmonary consequence of SCD is a pre-
dilection for pulmonary hypertension, a condition that
is linked to risk of sudden death in adulthood [30]. He-
molysis, which is a hallmark of SCD, appears to be
mechanistically linked with this clinical complication[31]. This is because of impaired nitric oxide (NO) bio-
availability, which appears to be the central feature of
endothelial dysfunction in SCD [32]. Thus, one might
predict that the abrogation of hemolysis through cor-
rection of SCD by successful BMT should also elimi-
nate any risk of developing pulmonary hypertension as
a consequence of hemolysis and NO depletion [33,34].
We have commenced a cross-sectional study of tricus-
pid regurgitant jet velocity in survivors of successful
BMT to explore this prediction.
A significant fraction of individuals developed
gonadal insufficiency after transplantation, and 3 post-
pubertal females were treated with hormone-replace-
ment therapy (Table 5). Together, these observations
tend to confirm the gonadal toxicity that occurs after
exposure to myeloablative (MA) doses of Bu, particu-
larly in the females [35–38]. Although formalized
studies of fertility per se were not conducted, many
of these survivors would be predicted to have infertil-
ity. Of interest, many of the males exhibited a pattern
of hypogondadotropic hypogonadism, which is often
associated with a central etiology, and which has
been observed in the setting of iron overload after
transplantation for thalassemia major. However,
a more likely explanation here is that the timing of
puberty in males with SCD can be delayed compared
to unaffected males [39], and that many of the males
studied had not yet achieved postpubertal status
when the posttransplant assessments were performed.
Additional follow-up in this cohort, particularly with
respect to fertility, will provide useful information to
physicians and families.
In summary, we observe that HLA-identical BMT
offers long-term protection from clinical and subclin-
ical vaso-occlusion, and thus should be offered sooner
and with greater frequency to families that might ben-
efit from this curative therapeutic option. However,
decision making must also take into account the risks
of transplantation, which include a significant risk of
infertility and gonadal dysfunction, and warrant the
application of transplantation in those who are most
likely to follow a morbid clinical course. Nonetheless,
it is hoped that this report might support a change in
the perception that only a very small fraction of chil-
dren are appropriate for BMT. The unfolding story
of SCD is that the scope of disease is far wider, rather
than more narrow than initially believed, which lends
considerable urgency to establishing and expanding
curative therapies for this disorder.ACKNOWLEDGMENTS
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